Boehringer Ingelheim, Ochre Bio Launch Up-to-$1B+ Liver Disease Partnership
Boehringer Ingelheim will apply Ochre Bio’s discovery platform to develop treatments for late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and other chronic liver diseases (CLDs), through a collaboration that could generate more than $1 billion for the British developer of RNA-based liver treatments.